pepdex
← Back to index
040

ARA-290 (Cibinetide)

EPO-derived peptide that targets the innate-repair receptor without the red-blood-cell side of erythropoietin. Studied for neuropathic pain, sarcoidosis, diabetic complications.

Healing
Evidence: Moderate
Half-life
~2 minutes (rapid clearance)
Route
Subcutaneous
Cycle
4-12 weeks
Schedule
Once daily
In plain English

ARA-290 is derived from EPO (erythropoietin) but doesn't bump red blood cells the way EPO does. It targets the innate-repair receptor instead. Real Phase 2 data for neuropathic pain and sarcoidosis. Useful for chronic nerve issues.

Status & legality
Natty?
Grey area
FDA
Not approved

Investigational. Phase 2 trials in sarcoidosis and diabetic neuropathy.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed

Doesn't trigger erythropoiesis like EPO does, but interpretation varies.

Prescribed

Not commercially available.

Who it's for

  • Users with neuropathic pain (small-fiber neuropathy)
  • Sarcoidosis patients (Phase 2 data)
  • Healing stacks for nerve-involved injuries

What to expect

  1. Week 1

    Subtle. Some neuropathic pain users notice first nerve-tingling reduction.

  2. Week 4

    Cumulative effect. Sarcoidosis trial endpoint.

  3. Week 8

    Sustained users see compounding benefits.

How it works (mechanism)

Erythropoietin-derived peptide that activates the innate-repair receptor (heteromer of EPO-R and CD131) without triggering erythropoiesis. Reduces inflammation and supports nerve and tissue healing without raising red blood cells.

Dosing protocol

2-4 mg sub-q daily.

Stacks well with

BPC-157 + TB-500 for nerve+tissue healing protocols
Standalone for neuropathic pain

Side effects

01Generally well tolerated
02Rare: mild headache
03Injection-site reaction

When NOT to use

  • Pregnancy / nursing
  • Active malignancy — limited data

Bloodwork to monitor

  • CBC (no measurable RBC effect, but cheap monitoring if running long)

Common mistakes

  • Expecting fast pain relief (cumulative over weeks)
  • Stopping too early
  • Underdosing — 1 mg often produces no measurable change

Drug & supplement interactions

  • Limited documented interactions
  • Doesn't trigger erythropoiesis like EPO does — less interaction with iron / hematinic agents

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is ARA-290 (Cibinetide)?+
ARA-290 is derived from EPO (erythropoietin) but doesn't bump red blood cells the way EPO does. It targets the innate-repair receptor instead. Real Phase 2 data for neuropathic pain and sarcoidosis. Useful for chronic nerve issues.
Is ARA-290 (Cibinetide) FDA approved?+
Investigational. Phase 2 trials in sarcoidosis and diabetic neuropathy.
Is ARA-290 (Cibinetide) banned by WADA?+
ARA-290 (Cibinetide) is not currently on the WADA prohibited list. Doesn't trigger erythropoiesis like EPO does, but interpretation varies.
Are you still natty after taking ARA-290 (Cibinetide)?+
Grey area. Federations differ on whether this disqualifies natty status.
Do doctors prescribe ARA-290 (Cibinetide)?+
Not commercially available.
What's the typical dose of ARA-290 (Cibinetide)?+
2-4 mg sub-q daily.
What are the side effects of ARA-290 (Cibinetide)?+
Common side effects include: Generally well tolerated; Rare: mild headache; Injection-site reaction. Less common effects and full safety details are on the entry page.
How long until ARA-290 (Cibinetide) starts working?+
Subtle. Some neuropathic pain users notice first nerve-tingling reduction.